Iovance Biotherapeutics Reports FDA Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

(24/7 MARKET NEWS) – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported, after Friday’s market close, that the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for lifileucel for patients with advanced melanoma.

Iovance Biotherapeutics is trading at $8.31, up $0.76 (+10.07%), on 4.66M shares traded.

Its 52-week range is $5.28 to $13.44. It’s trading just below a key inflection point and if it can trade and consolidate above $9.02, it should try to shoot for a run above its May 23 trading levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist